KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -8.19%.

  • Castle Biosciences' EBITDA Margin fell 1411.00% to -8.19% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.17%, marking a year-over-year decrease of 984.00%. This contributed to the annual value of 2.61% for FY2024, which is 3354.00% up from last year.
  • Castle Biosciences' EBITDA Margin amounted to -8.19% in Q3 2025, which was down 66.12% from -4.93% recorded in Q2 2025.
  • Castle Biosciences' 5-year EBITDA Margin high stood at 5.92% for Q3 2024, and its period low was -91.70% during Q1 2022.
  • Its 3-year average for EBITDA Margin is -16.13%, with a median of -8.19% in 2025.
  • In the last 5 years, Castle Biosciences' EBITDA Margin tumbled by 7,294bps in 2022 and then surged by 6,749bps in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' EBITDA Margin stood at -25.68% in 2021, then tumbled by 3,387bps to -59.55% in 2022, then surged by 5,100bps to -8.56% in 2023, then soared by 1,325bps to 4.69% in 2024, then plummeted by 1,411bps to -8.19% in 2025.
  • Its last three reported values are -8.19% in Q3 2025, -4.93% for Q2 2025, and -31.74% during Q1 2025.